Related references
Note: Only part of the references are listed.Bioinformatical Assistance of Selecting Anti-HIV Therapies: Where Do We Stand?
Thomas Lengauer
INTERVIROLOGY (2012)
European guidelines on the clinical management of HIV-1 tropism testing
L. P. R. Vandekerckhove et al.
LANCET INFECTIOUS DISEASES (2011)
HIV-1 Entry Cofactor: Functional cDNA Cloing of a Seven-Transmembrane, G protein-Coupled Receptor
Yu Feng et al.
JOURNAL OF IMMUNOLOGY (2011)
Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study
Patricia Recordon-Pinson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Prediction of HIV Type 1 Subtype C Tropism by Genotypic Algorithms Built From Subtype B Viruses
Stephanie Raymond et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Improved Prediction of HIV-1 Coreceptor Usage with Sequence Information from the Second Hypervariable Loop of gp120
Alexander Thielen et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Prediction of Co-Receptor Usage of HIV-1 from Genotype
J. Nikolaj Dybowski et al.
PLOS COMPUTATIONAL BIOLOGY (2010)
A Quantitative Affinity-Profiling System That Reveals Distinct CD4/CCR5 Usage Patterns among Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Strains
Samantha H. Johnston et al.
JOURNAL OF VIROLOGY (2009)
V3 Loop Sequence Space Analysis Suggests Different Evolutionary Patterns of CCR5-and CXCR4-Tropic HIV
Katarzyna Bozek et al.
PLOS ONE (2009)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage
Oliver Sander et al.
PLOS COMPUTATIONAL BIOLOGY (2007)
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
M Westby et al.
JOURNAL OF VIROLOGY (2006)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro
SJ Dai et al.
ACTA PHARMACOLOGICA SINICA (2005)
Bioconductor: open software development for computational biology and bioinformatics
RC Gentleman et al.
GENOME BIOLOGY (2004)
Virus entry as a target for anti-HIV intervention
JA Esté
CURRENT MEDICINAL CHEMISTRY (2003)
A new perspective on V3 phenotype prediction
S Pillai et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2003)
A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes
M Cavrois et al.
NATURE BIOTECHNOLOGY (2002)
Diversity of receptors binding HIV on dendritic cell subsets
SG Turville et al.
NATURE IMMUNOLOGY (2002)
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
A Trkola et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks
W Resch et al.
VIROLOGY (2001)
Ability of the v3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: Correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4
RE Means et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
